The Discounted Cash Flow (DCF) valuation of Alnylam Pharmaceuticals Inc (ALNY) is (136.63) USD. With the latest stock price at 418.91 USD, the upside of Alnylam Pharmaceuticals Inc based on DCF is -132.6%.
Based on the latest price of 418.91 USD and our DCF valuation, Alnylam Pharmaceuticals Inc (ALNY) is a sell. selling Alnylam stocks now will result in a potential gain of 132.6%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 7.1% - 9.0% | 8.1% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (254.11) - (94.98) | (136.63) |
| Upside | -160.7% - -122.7% | -132.6% |